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Background: Cancer stem cells (CSC) represent a rare fraction of cancer cells characterized by resistance to
chemotherapy and radiation, therefore nowadays there is great need to develop new targeted therapies for brain
tumors and our study aim to target pivotal transmembrane receptors such as Notch, EGFR and PDGFR, which are
already under investigation in clinical trials setting for the treatment of Glioblastoma Multiforme (GBM).
Methods: MTS assay was performed to evaluate cells response to pharmacological treatments. Quantitative RT-PCR
and Western blots were performed to state the expression of Notch1, EGFR and PDGFRα/β and the biological
effects exerted by either single or combined targeted therapy in GBM CSC. GBM CSC invasive ability was tested
in vitro in absence or presence of Notch and/or EGFR signaling inhibitors.
Results: In this study, we investigated gene expression and function of Notch1, EGFR and PDGFR to determine
their role among GBM tumor core- (c-CSC) vs. peritumor tissue-derived cancer stem cells (p-CSC) of six cases of
GBM. Notch inhibition significantly impaired cell growth of c-CSC compared to p-CSC pools, with no effects
observed in cell cycle distribution, apoptosis and cell invasion assays. Instead, anti-EGFR therapy induced cell cycle
arrest, sometimes associated with apoptosis and reduction of cell invasiveness in GBM CSC. In two cases, c-CSC
pools were more sensitive to simultaneous anti-Notch and anti-EGFR treatment than either therapy alone compared to
p-CSC, which were mostly resistant to treatment. We reported the overexpression of PDGFRα and its up-regulation
following anti-EGFR therapy in GBM p-CSC compared to c-CSC. RNA interference of PDGFRα significantly reduced cell
proliferation rate of p-CSC, while its pharmacological inhibition with Crenolanib impaired survival of both CSC pools,
whose effects in combination with EGFR inhibition were maximized.
Conclusions: We have used different drugs combination to identify the more effective therapeutic targets for GBM
CSC, particularly against GBM peritumor tissue-derived CSC, which are mostly resistant to treatments. Overall, our
results provide the rationale for simultaneous targeting of EGFR and PDGFR, which would be beneficial in the
treatment of GBM.Introduction
Glioblastoma multiforme (GBM) is an aggressive type of
brain cancer that resists treatment. Recently, it has been
established that in many types of cancer the bulk of cells
that make up a tumor are derived from a small popula-
tion of CSC, also known as tumor initiating cells. CSC
are distinguished from the bulk of the population of* Correspondence: cencia65@gmail.com
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article, unless otherwise stated.tumor cells by their ability to successfully seed new tu-
mors when implanted in low numbers into experimental
animals. Such cells are proposed to persist in recurrent
GBM and to have enhanced resistance to chemotherapy
and radiation-induced apoptosis [1].
The Notch pathway plays an important role in cellular
processes during embryonic and postnatal development,
including stem cells renewal, cell fate determination and
apoptosis. A role for Notch signaling in the maintenance
of cancer stem cells has been described in preclinical
models and recently in clinical studies [2-4]. Increasingtral Ltd. This is an Open Access article distributed under the terms of the
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receptors and Notch ligands in GBM, and their knockout
inhibit gliomas proliferation and survival. Therefore this
pathway could be considered as a therapeutic target for
cancer therapy [5,6]. Notch receptor is synthesized as an
inactive 300 kDa precursor protein, which is proteolytic-
ally cleaved by a furin-like convertase before it inserts as a
non-covalently bound heterodimer in the plasma mem-
brane There are four Notch receptors (Notch1, 2, 3 and 4)
and five ligands of the DSL (Delta and Serrate Ligands)
family, which includes Delta-like ligands (DLL) 1, 2, 3, and
Serrate/Jagged (JAG) 1 and 2. Members of both the Notch
receptor and DSL ligand families are, for the most part,
type I single-pass integral membrane proteins. Signaling is
initiated by binding of a Notch ligand expressed on one
cell to a Notch receptor on an adjacent cell. Upon ligand
binding to the receptor, Notch is sequentially cleaved
by ADAM10/TACE (a disintegrin and metalloproteinase)
and by a presenilin-dependent γ-secretase protease com-
plex which consists of presenilin 1 (PSEN1) or PSEN2,
Nicastrin, PEN2 and APH1 [7]. This process results in the
release in the cytoplasm of a soluble fragment consisting
of the entire intracellular domain, termed Notch intracel-
lular domain (NICD). After translocation to the nucleus,
NICD binds to transcription factor CSL, and converts a
large co-repressor in an active transcriptional complex
that activates the transcription of Notch target genes.
These include genes encoding Hairy Enhancer of Split
(HES1), HES-related proteins (HEY), p21waf1, Cyclin D1
and 3, c-myc, and HER2 [8-11].
A number of genetic alterations are responsible for the
malignancy of GBM, often mutations leading to the
hyperactivation of receptor tyrosine kinases (RTK). A
combination of proteomic and genomic analyses of 243
GBM from The Cancer Genome Atlas (TCGA), subdivides
these tumors into three subclasses based on the pattern
of expression and genetic alterations: classical/EGFR+,
proneural/PDGFR + and mesenchymal/NF1+ classes [12].
Le Mercier et al. [13], report that the addition of temo-
zolomide to conventional radiotherapy significantly im-
proved the survival of patients belonging to the classical
subtype, but it did not affect the survival of patients
belonging to the proneural subtype, suggesting the im-
portance to clinically subdividing patients in order to de-
vise the best targeted therapy. EGFR is overexpressed
in almost 40-50% of GBM and contributes to uncontrolled
proliferation and survival of glioma cells [14]. A well-
documented alteration in GBM is the amplification and
activating mutation of EGFR variant III (EGFRvIII). EGFR-
vIII has an overall prevalence of almost 60% in patients
whose tumors show amplification of wild type (wt) EGFR
[15,16]. Enhanced activation of RTK leads to the acti-
vation of intracellular signaling pathways such as the
Raf/MEK/Erk and the PI3K/Akt pathways, which areultimately responsible for the malignant phenotype of
glioma cells [17].
Another subset of gliomas, the PDGFR subclass account
for 25-30% of GBM, and is characterized by dysregulation
of PDGFR activity, which in some cases is due to amplifi-
cation and rearrangements of the PDGFRα gene locus,
and in others to overexpression of the PDGF ligands
[12,18,19]. PDGFR is a transmembrane receptor with 5
immunoglobulin-like repeats in its extracellular domain
and a tyrosine kinase in its intracellular domain. There
are four PDGF ligands (PDGF-A, PDGF-B, PDGF-C
and PDGF-D) that dimerize and bind to PDGF recep-
tors, PDGFRα and PDGFRβ [20]. PDGF-A, PDGF-B,
and PDGF-C bind to PDGFRα; PDGF-B and PDGF-D
bind to PDGFRβ. The binding of a ligand to the receptor
induces its autophosphorylation and activation of pivotal
intracellular signals (MAP kinase, PI3K/Akt, JAK/STAT
and PLC-PKC), which results in proliferation, survival,
migration and oncogenesis [21]. Recently, Kim et al.
[22] report that genetic or pharmacological targeting of
PDGFRβ in selected CD133 positive GBM CSC (but not
PDGFRα), attenuated self-renewal, survival, tumor growth
and invasion. Therefore, development of specific therapies
using tyrosine kinase inhibitors (TKI) targeted toward CSC
holds promise, but cancer cells may acquire resistance to
TKI. In fact, it has been reported that EGFR-mutant glio-
blastomas may evade EGFR TKI by transcriptionally de-
repressing PDGFRβ [23].
The current study aims to devise strategies to select-
ively target pivotal plasma membrane receptors relevant
to maintenance of either core tumor- (c-CSC) or peritu-
mor tissue (p-CSC)-derived GBM cancer stem cells. We
investigated the biological effects on these classes of
CSC mediated by TKI targeting individually Notch1,
EGFR and PDGFR signaling respectively. Combination
therapy with EGFR and Notch inhibitors provided more
significant therapeutic effects than single therapy alone,
promoting in some cases more apoptosis in c-CSC than
p-CSC. The combination of EGFR and PDGFR inhibi-
tors sensitizes either the most resistant GBM p-CSC or
c-CSC to apoptosis. This finding is highly relevant because
the peripheral area of the tumor is the site of recurrent
GBM in 90% of cases. The in vitro pharmacological stud-
ies on CSC are a such compelling model as they hold the
potential to develop new therapeutic strategies before
employing them in clinical trials.
Results
GBM CSC culture and evaluation of Notch1 and RTKs
gene expression
Cancer stem cells from GBM were isolated using defined
criteria set up by neurosurgeons as described previously
[24,25]. We can summarize these briefly: lesion removal
was achieved with resection margins that included the
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(between 1-2 cm from the tumor border; larger resec-
tions were performed in tumors that grew far from
eloquent areas), which were removed entirely en bloc.
Neuronavigation and intraoperative ultrasound were
used to maximize the extent of intracranial tumor resec-
tion. From this bulk we retrieved either core- (c-CSC) or
peritumor tissue-derived cancer stem cells (p-CSC). Cyto-
genetic and molecular analysis showed that the two
types of CSC have quite diverse tumorigenic potential
and distinct genetic anomalies [24]. Neurospheres of dif-
ferent sizes were obtained from cores of multiple speci-
men of GBM patients; these continued to propagate in
suspension in long-term culture. CSC derived from peri-
tumor tissue of GBM at early passages exhibited a differ-
ent phenotypic behavior compared to c-CSC: they grew at
a slow rate, forming small spheres, most of them attachedFigure 1 RT-PCR and protein expression analysis in GBM core- and p-
expressed in p-CSC3 and p-CSC4 compared to relative counterparts c-CSC.
1-3-4, but in case 2 occurs the opposite. (D) Custom RNA macroarray analy
several components of Notch pathway in p-CSC3, while the opposite was
RTK in GBM: EGFR (p-EGFR), PDGFRα and β isoforms and the active Notch1
PDGFRα abundance is an hallmark property of all p-CSC pools which sugg
distinct growth factor response. c-Myc is abundantly expressed in all pa
variant III. Error bars represent the mean ± SD (n = 3).to the plastic dishes. These latter particular morphological
features, in some cases, were gradually lost at late passages
in culture (data not shown).
To understand how Notch1 and epidermal growth fac-
tor receptor (EGFR) signaling would affect cell growth
and survival of GBM CSC, we first assessed the mRNA
expression profile in six human cases, consisting of paired
samples of c-CSC and p-CSC, for a total number of twelve
CSC. RT-PCR experiments for NOTCH1, HES1, EGFR wt
and variant EGFRvIII, were performed in triplicate for
each sample and the relative expression reported as -ΔCt
(Figure 1A-C). Notably, the p-CSC3 and p-CSC4 showed
a significant up regulation of NOTCH1 gene compared to
relative c-CSC, either at mRNAs level or the protein con-
tent of the Notch intracellular domain 1 NICD1, (the ac-
tive form of Notch1) (Figure 1A, E). We carried out in
parallel a custom RT-PCR array in the most studied casesCSC. (A-B) NOTCH1 and his gene target HES1 mRNA levels are highly
C, EGFR mRNA expression results more abundant in c-CSC of cases
sis performed in the first three cases reveals the up regulation of
detected in Cases 1 and 2. (E) Western blot analysis of more relevant
(NICD1), Notch ligand delta-like 1 (Dll1) and Notch1 gene target Hes1.
ests the presence of a cell subpopulation in p-CSC with probably
irs of CSC examined. Arrows denote the doublet of EGFR full-length and
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lation of Notch signaling components in p-CSC3 ver-
sus c-CSC3, expressed as fold change (Fc) and including:
NOTCH3 (4.78 Fc), Nicastrin (NCSTN, 3.4 Fc), Prese-
nilin1 (PSEN1, 2.39 FC), Mastermind-like 1-2 (MAML1,
MAML2, 2.36 and 3.24 FC respectively), Delta-Like
Ligand 1, (DLL1, 7.91 Fc), and Serrate Ligand Jagged2,
(JAG2, 3.66 Fc) (Figure 1B, C). The high mRNA levels of
HES1, a Notch1 primary target gene, directly correlated to
those of Notch1 in p-CSC3 and p-CSC4, suggesting a
Notch1 dependent mechanism for Hes1 gene regulation
(Figure 1A, B). Conversely, the high levels of HES1 mRNA
inversely correlated to Notch1 gene expression in p-CSC2
(Figure 1A, B), suggesting that other signals converged in
case-2 for HES1 gene transcription. A custom RT-PCR
array for genes encoding Notch signaling components
confirmed the reduction of Notch1 activation in p-CSC2
as well as NICD1 protein expression as compared to
c-CSC2 (Figure 1D, E). Hes1 protein was detected in
all CSC, raising the possibility that further mechanisms
may contribute to Hes1 protein stability through the
sonic hedgehog pathway as well as post-translational
processes [26,27].
The only mRNA positivity relative to EGFRvIII was
found in c-CSC1, which represent around 16% of the spec-
imens studied. EGFR mRNA expression was up modulatedFigure 2 Differential response of the GBM CSC to GSI-X and AG1478
pools after 3 and 5 days of treatment as compared to p-CSC pools by MTS
inhibition. Concurrent EGFR and Notch1 inhibition results in a synergistic a
relative p-CSC pools. Error bars represent the mean ± SD (n = 3). All dat
conducted three times.in c-CSC1, 3 and 4, down modulated in c-CSC2 compared
to relative counterparts, or unmodulated in the rest of the
cases (Figure 1C). EGFR protein expression mirrored the
levels of transcripts in the same samples. We extended our
protein analysis to another RTK, the platelet derived
growth factor receptor isoforms α and β (PDGFRα/β). The
inherent over expression of PDGFRα in p-CSC pools sug-
gests this as a molecular signature of the GBM peritumor
tissues, while PDGFRβ was expressed either in c-CSC or
p-CSC of the six cases examined (although we have docu-
mented increasingly expression levels in p-CSC pools ex-
cept for Case 6) (Figure 1E). We also reported the over
expression of c-Myc, a direct target of Notch1 [10], which
was equally express in all CSC.
Differential response of GBM CSC to treatment with GSI-X
and AG1478
CSC undergoing treatment with γ-secretase inhibitor-X
(GSI-X), a Notch signaling inhibitor, either alone or along
with an EGFR signaling inhibitor AG1478, were evaluated
for any changes in cellular response by MTS assay. Here,
the experiments were conducted only on cases 1, 2 and 3
(Figure 2). c-CSC2 and c-CSC3 were significantly sensi-
tized with 2 μM of GSI-X after 3 days. Conversely, p-CSC2
showed an increase of cell proliferation, while p-CSC3
were not affected even at higher concentration of GSI-Xtreatment. (A) GSI-X negatively affect cell proliferation of GBM c-CSC
assay. (B) GBM CSC proliferation decrease after 2 days by single EGFR
nti-proliferative effect in c-CSC2 and c-CSC3 pools as compared to
a shown are representative of results obtained from experiments
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p-CSC1 showed resistance to the treatment after 3 days
(Figure 3A); instead the treatment on the 5th day dropped
proliferation of c-CSC1 to 70 ± 4.6% (Figure 2A). The
treatment with 10 μM of AG1478 resulted in a significant
sensitization of all six CSC as detected by MTS assay
(Figure 2B).
No close correlation between sensitization to AG1478
with the levels or the mutational state of EGFR gene was
found (Figure 1C, E). In fact, cell proliferation decreased
to 28.3 ± 6.1% and 30,9 ± 8.3% in c-CSC1 and p-CSC1,
respectively (Figure 2B), although c-CSC1 would overex-
press both full-length and the variant III of EGFR
(Figure 1E). In c-CSC2 and c-CSC3 cell proliferation
dropped to 44,8 ± 6.4% and 49 ± 2.1% respectively
against to 59.2 ± 4.1% of p-CSC2 and 65.2 ± 5.5% of
p-CSC3. The treatment with the two inhibitors caused
a synergistic anti-proliferative effect in c-CSC2 and
c-CSC3, bringing cell proliferation down to 19 ± 8.3%
and 34 ± 3.8% respectively (Figure 2B), while growth of
p-CSC2 and p-CSC3 remained unmodified at 57 ± 2.9%
and 70 ± 5.6%, respectively. This finding argued for a
stronger anti-Notch1 and EGFR resistance of p-CSC vs.
c-CSC pools, at least in these 2 cases.
To substantiate the effects observed by MTS assay, we
carried out Western blots analysis for the main signal
molecules relevant for proliferation and cell survivalFigure 3 Dual inhibition contributes to down modulation of PI3K/Akt
Case 1 reveal none modulation of Notch1 target Hes1 protein by GSI-X. EG
or EGFRvIII. p-Akt1 (S473) and p-ERK1/2 (T202/Y204) disappear with the dua
was maintained high in p-CSC1 after treatment, and probably contribute to d
target Hes1 protein in both pools of Case 2. Decrease of p-Akt1 protein levels
following dual treatment. Higher levels of p-Stat3 in p-CSC2 compared to c-C
alone or combined with GSI-X downmodulates the levels of p-Stat3 and PDG
EGFR and PDGFRβ protein expression between core- and p-CSC3. c-CSC3 sho
AG1478 causes p-Erk1/2 decrease but not p-Akt1. Dual treatment triggers a d
contrary, p-CSC3 pool maintains an high expression of p-Akt1, p-Erk1/2, PDGF
the high cell drug resistance. Arrows denote the doublet of EGFR full-length a(Figure 3). The concentration of the inhibitors used in
our treatment was effective in inhibiting Notch1 cleav-
age and EGFR phosphorylation on Try1068. Notably,
only c-CSC1 showed a protein doublet of 180 and 140
KDa (corresponding to the full-length and EGFRvIII re-
spectively); the rest of cases displayed the full lenght iso-
form (Figure 3). We evaluated the activation and
modulation of the main downstream effectors of EGFR
signaling, such as Akt1, Erk1/2 and Stat3, after two days
of treatment. No significant changes of phosphorylation
state of p-Akt1 and p-Erk1/2 were found in the three
cases examined after 2 days of treatment with GSI-X.
p-CSC3 displayed resistance even to higher concentration
of GSI-X (Additional file 1: Figure S1). Conversely,
p-Erk1/2 was suppressed in case 1, and significantly down
modulated in case 2 and 3, except for p-CSC3, following
AG1478 treatment. The combination of the two agents
suppressed p-Erk1/2 expression in case 2 and 3, but it
was still preserved in p-CSC3 and similarly results were
seen for p-Akt-1 activation. Stat3 phosphorylation on
Y705 has been shown to be directly mediated by EGFR
or indirectly by proteins of JAK family. EGFR signaling
inhibition caused a decrease of phosphorylation of
p-Stat3 in case 2 and c-CSC3, conversely in p-CSC1 and
p-CSC3 the levels of p-Stat3 were unmodulated, suggest-
ing a mechanism of resistance to EGFR TKI treatment
in these cases. PDGFRβ was more expressed in p-CSC, ERK1/2 and Jak/STAT3 pathways in GBM CSC. (A) Western blots in
FR inhibition affects the phosphorylation status either of the full-lenght
l treatment in both of pools, but p-Stat3 (Y705) and PDGFRβ expression
rug resistance. (B) Western blot analysis reveal no modulation of Notch1
by GSI-X in c-CSC2 but not in p-CSC2. Either p-Erk1/2 or p-Akt1 disappear
SC2 may contribute to drug resistance as observed in p-CSC1. AG1478
FRβ. (C) Western blot analysis detects significant differences in NICD1,
w no modulation of p-Akt1 and p-Erk1/2 by Notch inhibition, while
ecrease of p-Stat3 with a significant loss of p-Akt1 in c-CSC3. On the
Rβ and p-Stat3 either after AG1478 or dual treatment, which may explain
nd EGFRvIII.
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or AG1478 alone, except for CSC2 that showed PDGFRβ
down modulation by AG1478 treatment (Figure 3A-C).
Simultaneous GSI-X and AG1478 treatment trigger apoptosis
in core-CSC
The main biological responses of cancer stem cells de-
scribed in the literature following treatment with Notch
inhibitors are: arrested cells and induction of apoptosis.
Flow cytometry analyses showed a moderate apoptosis/
necrosis induced by GSI-X, which resulted 4.7% and 12%
in c-CSC2 and c-CSC3 respectively respect to 0.3% and
5% in DMSO-treated cells (Figure 4B, C). Single AG1478
treatment was more effective than GSI-X, as c-CSC2 and
c-CSC3 were both shifted in G1 phase (61.8% and 82.1%
respectively as compared to 54.2% and 74.5% in DMSO-
treated cells) and induced to apoptosis/necrosis (9% and
10%, respectively).
Dual treatment raised apoptosis/necrosis to 10.2% in
c-CSC2 and 27% in c-CSC3. These results were verified by
induction of Caspase-3 and PARP-1 cleavage, reduction of
both Survivin and Cyclin D1 as reported by Western blots
(Figure 4B, C). AG1478 determined the accumulation of
p-CSC2 in G1 phase (74,9%), while the dual treatment
raised this to 78,7% compared to 61.3% in DMSO-treated
cells. The slowing of cell cycle progression was asso-
ciated with loss of Cyclin D1 and increase of p27Kip,
but we monitored very low levels of Caspase-3 and
PARP-1 cleavage fragments, and no effect on Survivin
protein levels. Conversely, p-CSC3 were fully resistant to
treatment (Figure 4C). EGFR inhibition induced cell cycle
arrest of both c-CSC1 and p-CSC1 which amounted to
84.3% and 87.9% respectively versus 66.2% and 58.1% in
DMSO-treated cells. This finding correlated with high in-
duction of p27Kip1 (Figure 4A). Cyclin D1 was not detected
by Western blots, although mRNAs were monitored by
custom RT-PCR array (data not shown).
Cell invasion properties of GBM CSC
In order to assess the invasion capabilities of CSC and
the effects of the inhibitors either alone or in combin-
ation a matrigel invasion assay was performed. To in-
vade the cells need an active process that involves cell
motility and extracellular matrix proteolysis, and for this
reason we monitored the expression of MMP-9, matrix
metallopeptidase-9, which belongs to MMP family in-
volved in tumor progression, including invasion and
cancer metastasis [28]. Cell invasion ability was assessed
in cases 1, 2 and 3 in absence or presence of growth fac-
tors (GF). In absence of GF, both p-CSC1 and p-CSC2
hold higher invasive ability compared to relative coun-
terparts; conversely, c-CSC3 are much more invasive
than p-CSC3. Following addition of GF, all CSC moved
significantly through the plastic insert of the trans-wellsdishes (Figure 5A-C). GSI-X treatment did not affect the
invasive ability of any CSC, except for c-CSC3, although
other authors report that genetic Notch1 knockdown re-
sulted in reduced cell migration invasion in a glioma cell
line by inhibition of β-catenin and NF-κB signaling [29].
It has been reported that EGFR inhibition efficiently
blocked EGF-induced activation of MMP9 and cancer
invasiveness [30]. In our work AG1478 treatment in-
duced differential effects, in part explained by the RTK
profile. AG1478 inhibited cell invasion and MMP9 pro-
tein expression in c-CSC1 and p-CSC1, whereas the
combination therapy resulted in suppression of MMP-9
(Figure 5A). AG1478 alone did not affect the invasive
ability of c-CSC2 and p-CSC2, but the dual treatment in-
fluenced significantly both pools of cells and directly cor-
related with a stronger reduction of MMP-9 in c-CSC2
than in p-CSC2 (Figure 5B). Similar outcomes were ob-
tained in c-CSC3, and the influence of this combination
treatment was superior to monotherapy with AG1478.
Conversely, p-CSC3 had a modest invasion ability com-
pared to c-CSC3, probably due to intrinsic reduced ex-
pression of EGFR (Figure 5C).
Combination of AG1478 and Crenolanib triggers
apoptosis in both GBM CSC pools
The high PDGFRα protein expression reported in all
p-CSC of the six cases examined, prompted us to test the
pharmacological inhibition of PDGFRα to evaluate its im-
pact on cell growth and survival of CSC. In this study,
EGFR signaling inhibition have been shown to be more ef-
fective therapeutically than GSI-X, suggesting that the
combination with Crenolanib (CR, a selective inhibitor of
PDGFRα), would enhance the growth inhibitory effect
especially in p-CSC, which were more resistant to treat-
ments. As reported in Figure 6A, B, we observed a signifi-
cant decrease of cell proliferation in both c-CSC1 and
p-CSC1 (38 ± 9.5% and 56 ± 4.4% respectively) with CR
(10 μM) alone after 1 day of treatment by MTS assay, but
when used in combination with AG1478 (10 μM) the aver-
age values declined to 24 ± 9.6% and 34 ± 9.9% respectively.
In addition, Western blots analysis clearly showed an in-
duction of Caspase-3 and PARP-1 cleavage fragments, the
effect of which was maximized by combining the two in-
hibitors (Figure 7A). Of note, is the de-repression of
PDGFRα in AG1478-treated CSC1 as well as in p-CSC2
(Figure 7B), this is probably due to a compensatory activa-
tion mechanism to evade EGFR TKI. In addition, we
detected a downmodulation of PDGFRα expression
following Crenolanib treatment, which was a common
feature in all cases examined (Figure 7A-C). We applied
the same treatments to CSC2 and CSC3 (Figure 6C-F).
The MTS assay monitored a significant reduction of cell
proliferation to 65 ± 2.6% and 47 ± 5% in c-CSC2 and c-
CSC3 respectively, while in p-CSC2 and p-CSC3 cell
Figure 4 Simultaneous targeting of Notch1 and EGFR signaling induces apoptosis in GBM c-CSC2 and c-CSC3 but not in CSC1. (A) No induction
of Caspase-3 and PARP-1 fragments cleavage following drug exposure was monitored. AG1478 induces an high expression of cell cycle regulatory protein
p27kip in c-CSC1 and p-CSC1. This finding correlates to a strong shifting from S to G0/G1 phase of cell cycle in both pools as observed by Flow cytometry.
CycD1 was not detected by immunoblotting. (B) Appearance of Caspase-3 (17-19 KDa fragments) and PARP-1 (116-89 KDa) fragments are monitored in
c-CSC2 either in presence of AG1478 or in combination with GSI-X, while in the p-CSC2 this phenomenon is present but at lesser extent. GSI-X treatment
induced a modest apoptosis/necrosis effect preferentially in c-CSC2 and did not affect cell cycle distribution. EGFR signaling inhibition induces apoptosis/
necrosis only in c-CSC2 pool, while AG1478 induces a consistent shifting to G1/G0 in p-CSC2 respect to c-CSC2, which correlated with higher levels of
p27kip. Cyclin D1 protein is down modulated in both cell populations of case 2 by EGFR inhibition, instead the antiapoptotic protein Survivin declines
preferentially in c-CSC2 by the dual blockade, suggesting that the combination therapy is more effective in the c-CSC2 than in p-CSC2. (C) GSI-X and
AG1478 concurrently added in c-CSC3 resulted in Caspase-3 and PARP-1 fragments cleavage, decrease of both Cyclin D1 and Survivin expression.
AG1478 induces a shift to G0/G1 phase in c-CSC3 and the drugs combination potentiates the apoptotic effect in c-CSC3. p-CSC3 are refractory to any
drug blockade as reported by flow cytometry and Western blots analysis. Lower arrows indicate the fragments cleavage of Caspase-3 and PARP-1.
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with CR alone. Dual treatment was more effective than
treatment alone in both CSC2 and CSC3, as reported in
Figure 6C-F. Of note, as early as the first day of treatment
the two agents exerted a synergistic antiproliferative effect
in CSC2 and CSC3 with induction of Caspase-3 and
PARP-1 cleavage and reduction of p-Akt1 in CSC3 or Bcl2
in CSC2 (Figure 7B, C).Modulation of PDGFRα activity regulates cell growth and
survival pathways in GBM CSC
To confirm the pivotal role of PDGFRα in cell prolifera-
tion, we downregulated his expression by short hairpin
RNA mediated-knockdown in p-CSC2. After a brief period
of antibiotic selection, either control infect cells (pLKO.1)
or two cell clones expressing shPDGFRα were plated
for cell growth assessment. shPDGFRα-cells showed a
Figure 5 (See legend on next page.)
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Figure 6 AG1478 and Crenolanib trigger cell growth inhibition in both c-CSC and p-CSC. (A, B) AG1478 alone or in combination with CR
determine a significant antiproliferative effect in c-CSC1 and p-CSC1 either at 1 day or 2 days of treatment. No synergistic antiproliferative effect is
monitored with the combination therapy. (C, D) AG1478 alone or in combination with CR determine a significant antiproliferative effect in c-CSC2 and
p-CSC2 either at 1 day or 2 days of treatment. The combination therapy triggers a synergistic antiproliferative effect in p-CSC2 at day 1. (E, F) AG1478
and CR provided alone determine a significant antiproliferative effect in c-CSC3 and p-CSC3 either at 1 day or 2 days of treatment. The combination
therapy triggers a synergistic antiproliferative effect in both c-CSC3 and p-CSC3 at day 1 of treatment. Error bars represent the mean ± SD (n = 3). All
data shown are representative of results obtained from experiments conducted twice.
(See figure on previous page.)
Figure 5 Cell invasion properties of GBM CSC. (A) In absence of GF p-CSC1 have higher invasive ability than c-CSC1 on matrigel invasion
assay. Addition of GF promotes invasiveness of both cell populations of case 1, which is blocked by AG1478. Drugs combination don’t improve
the effect of monotherapy but induces a strong repression of MMP9 protein expression. The values of MMP9 repression are calculated respect
to DMSO-vehicle. (B) In absence of GF, p-CSC2 have higher invasive ability than c-CSC2. Addition of GF promotes the invasiveness of both cell
populations of case 2 but only the combination of GSI-X and AG1478 significantly impairs the invasive performance of c-CSC2 and p-CSC2, which
correlates to reduction of MMP9 protein. The values of MMP9 repression are calculated respect to DMSO-vehicle. (C) In absence of GF c-CSC3
holds higher invasive ability than p-CSC3 and similarly to other cases the addition of GF favors significantly their invasive features. AG1478 impairs
c-CSC3 invasion but not p-CSC3. Moreover, drug combination increases the effect of AG1478 monotherapy only in c-CSC3. This finding correlates
to a decline of MMP9 protein expression. Conversely, p-CSC3 shows drug resistance and retains high levels of MMP9. The values of MMP9 repression
are calculated respect to DMSO-vehicle. Error bars represent the mean ± SD (n = 3). All data shown are representative of results obtained from
experiments conducted three times.
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Figure 7 Down modulation of PDGFR activity affects cell growth and survival of GBM CSC. (A-C) Concurrent treatment with Crenolanib
and AG1478 enhances apoptosis as monitored by Caspase-3 and PARP-1 cleavage, either in GBM c-CSC or p-CSC, except for p-CSC3. Instead,
Crenolanib alone is less effective in inducing apoptosis either in c-CSC or p-CSC pools. High PDGFRα expression is a distinctive feature of p-CSC
pools and its expression is de-repressed following AG1478 treatment clearly evident in case 1 and 2, while its expression is downmodulated
following Crenolanib treatment in all cases reported. (D) Cell growth assay of shPDGFRα-p-CSC2 clones (cl.1 and 3) displays a significant reduction
of cell proliferation with respect to control cells (pLKO.1). Data shown are representative of results obtained from experiments conducted two
times. Western blots display downmodulation of PDGFRα in shPDGFRα-p-CSC2 clone 1 and 3, but not of PDGFRβ. (E) c-CSC2 and p-CSC2 starved
for 2 days and undergoing PDGFAA stimulation, manifest early phosphorylation of Akt1 and Erk1/2 in p-CSC2 but not in c-CSC2. No effects were
observed on STAT3 phosphorylation upon PDGFAA stimulation. Expression of Cyclin D1 protein serves as a control of cell starvation. ns denotes
not specific bands.
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pLKO.1 cells, which was consistently maintained up to
the seventh day in culture (Figure 7D). In order to evalu-
ate p-CSC response to PDGFAA, c-CSC2 and p-CSC2
were undergone to growth factors (EGF and bFGF)
deprivation for 2 days, and then exposed to PDGFAA
(40 ng/ml) for short periods of time (Figure 7E). PDGFAA
stimulation induced early activation of p-Erk1/2 and
p-Akt1 in p-CSC2 within 5 minutes, which declined to
basal levels later. Conversely, c-CSC2 displayed a faint re-
sponse to PDGFAA.
Discussion
In recent years, aberrant RTK expression has gained much
attention in cancer stem cells biology. Several TKI andblocking antibodies anti-EGFR have been tested and others
are currently in 30 ongoing clinical studies for GBM treat-
ment, according to the website of clinicaltrial.gov (United
States National Institutes of Health). Despite the seemingly
critical role of EGFR signaling in GBM, only 10 to 20 per-
cent of patients have shown a modest improvement by
EGFR kinase inhibitors [30,31]. These initials clinical re-
sults have demonstrated the need to understand GBM’s
resistance mechanisms to EGFR inhibition as well as to
other inhibitors in order to develop more effective therap-
ies [32]. A sub-population of CD133 positive cancer stem
cells with higher Notch activity has been identified in
GBM [33]. Notch inhibition by γ-secretase inhibitors
depleted CD133+ glioblastoma cells, making these com-
pounds potential chemotherapeutic agents to target high-
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study with MK-0752 (a gamma-secretase inhibitor devel-
oped by Merck), demonstrated clinical benefits in patients
with advanced solid tumors, including GBM, and now
combination trials are ongoing to maximize the therapeu-
tics benefit with this novel agent [34].
PDGFRα is another critical gene in glioma biology, as
it is the second most frequently mutated TRK in GBM,
following EGFR. Similar to EGFR, PDGFRα has been
shown to be overexpressed, amplified, mutated and rear-
ranged in GBM. PDGFRα gene amplification could be
used as a potential prognostic biomarker and therapeutic
target in GBM [35]. A phase II study with a monoclonal
antibody anti-PDGFRα is under investigation in recur-
rent GBM.
In the current study we assessed the effects of Notch1,
EGFR and PDGFR inhibitors as a means of investigating
GBM CSC responses to disruption of specific intracellular
signaling relevant to GBM CSC maintenance. We identified,
in some cases, a heterogeneous expression of NOTCH1
gene, in particular we reported sustained levels of expres-
sion in p-CSC3 and p-CSC4 with respect to relative coun-
terparts c-CSC. In three cases deeply investigated, c-CSC
pools were impaired in cell growth by GSI-X, while the
relative p-CSC pools resisted treatment or delayed the in-
hibitory effects. The Notch1 pathway was investigated in
more detail in three cases and surprisingly we found that
Notch1 target Hes1 protein was not down modulated by
Notch inhibition. This finding may be explained by the
results of Wall et al. [28], who demonstrated that sonic
hedgehog (shh)-driven stabilization of Hes1 was inde-
pendent of Notch signaling and required the Shh effector
Gli2. Moreover, a physiological crosstalk has been pro-
vided between Notch-Hes1 and JAK-STAT pathways in
the developing central nervous system, as Hes proteins
(Hes1 and Hes5) bind to STAT3 directly, thereby suggest-
ing that Hes proteins may function as non-scaffold pro-
teins that allow JAK2 to phosphorylate STAT3 [36]. More
recently, other authors report that STAT3 and NF-κB sig-
naling regulates the Notch pathway in glioblastoma cancer
stem cells [37]. It is possible that as a consequence of this
complex interactions, Notch pathway would be partially
hampered by GSI-X treatment, as we detected uncertain
down modulation of the cell cycle progression protein
CycD1 in c-CSC2 (but not of p27), and of the anti-
apoptotic protein survivin in c-CSC3 (but not of Bcl2).
Based on the above results only a small fraction of cell
death was monitored in GSI-treated c-CSC.
A study on 196 cases of GBM from the TCGA consor-
tium, reports that the expression of Notch signaling com-
ponents was enriched in the classical/proliferative GBM
subtype characterized by EGFR+/PDGFRA- and in the
proneural subtype, characterized by PDGFRA+/IDH1+
[38], indeed we did find these correlations in our GBMCSC. Accordingly to the literature, fifty percent of GBM
CSC examined in the current study had shown overexpres-
sion of EGFR, which resulted independently from Notch1
activation, despite other laboratories’ reports that Notch
and EGFR signaling pathways converge to regulate the
same gene targets. Purow et al. [39], report that Notch1
regulates transcription of EGFR through p53 and Xu et al.
[40], stated that knockdown of Notch1 expression by
siRNA downregulated the expression of EGFR and the im-
portant components of its downstream pathways, includ-
ing PI3K/Akt, K-Ras, Cyclin D1 and MMP9.
The high EGFR expression in GBM CSC prompted us
to explore EGFR signaling as a therapeutic approach and
afterwards we decided on combinatorial therapy anti-
Notch and anti-EGFR. Our and other laboratories have re-
ported that a specific inhibitor for EGFR efficiently
blocked EGF-induced activation of MMP9 and reduced
cancer invasiveness [40]. The inhibitory effects of AG1478
on CSC invasive ability would impact consequently also
STAT3 signaling [41], as reported in the current study
except for p-CSC1 and p-CSC3, for whose we did not
observed any modulation of phosphorylation on Y705-
STAT3 following AG1478 treatment. STAT3 signaling is
also involved in GBM invasion promotive effect of IL-6
[42]. The combination of AG1478 and GSI-X exceeded
the effects of monotherapy as reported in Western blots,
flow cytometry and cell invasion assays. The uncertain
effects mediated by Notch inhibition alone were clearly
overridden by combining AG1478, which produced: i)
apoptosis, ii) switch-off of p-Akt1 and p-Erk1/2 expres-
sion, and iii) reduction of CycD1 and Survivin, except in
the most resistant p-CSC3 and the arrested CSC1. These
effects mirrored a marked reduction of CSC invasive abil-
ity with MMP9 protein down modulation as observed in
most of the cases except for p-CSC3.
EGFR has been the focus of many brain tumor studies
and it is noteworthy that expression of wild-type or con-
stitutively active mutant EGFR is rarely oncogenic as a
single lesion, whereas expression of PDGFR ligands can
induce tumors as a single driving event [43,18]. PDGFs
and PDGFRs deregulated expression are found even in
low-grade gliomas [43-45], suggesting that this pathway
is possibly an early oncogenic event, in contrast to EGFR
which is much more commonly found in high-grade gli-
omas [46]. Here we report for the first time the inherent
overexpression of PDGFRα in GBM p-CSC with respect to
c-CSC in all six patient samples examined, suggesting the
dominance of its signal in proliferation and maintenance
of GBM and in particular of peritumor tissue-derived CSC.
Recently, it has been reported that tyrosine-protein phos-
phatase non-receptor type 11 (SHP-2) and PI3K mediate
PDGFRα-promoted glioma tumor growth and invasion
[47]. Based on our results and those of other authors, we
hypothesize that the combinations of abnormal expression
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PDGFRα, PDGFRβ and Notch1 in GBM CSC or -derived
cell lines may influence cell response to targeted therapies,
thereby limiting the efficacy of single anti-EGFR or anti-
PDGFR or anti-Notch1 therapies as we have seen in this
study [48,49].
To demonstrate that PDGFRα was relevant to GBM
CSC maintenance, we tested a potent PDGFRα signaling
inhibitor Crenolanib in the most studied cases (cases 1-3).
A significant reduction of cell growth of either c-CSC or
p-CSC was reported, with remarkable effects on the 2nd
day of treatment on p-CSC3. The combination therapy
with AG1478 enhanced apoptosis induced by CR alone,
supporting the hypothesis that targeting more RTKs
would probably weaken the tumor growth. It is important
to note the up regulation of PDGFRα protein observed in
some cases in response to EGFR inhibition, which sug-
gests its role in mediating AG1478 resistance in GBM.
Recently, it has been reported that this event is emerging
as a frequent, non-genetic mechanism of targeted cancer
drug resistance, as reported in GBM CSC, colorectal can-
cer cells and in non-small cell lung cancer [23]. In addition,
genetic knockdown of PDGFRα in p-CSC2 caused slow-
down of cell growth rate and exogenous PDGFAA stimula-
tion of starved GBM CSC promoted p-Erk1/2 and p-Akt1
activation in p-CSC, confirming the concept that PDGFRα
activation provided survival signals in p-CSC vs. c-CSC.
Conclusions
Our results collectively support a key role of EGFR and
PDGFRα signaling in survival of Glioblastoma cancer stem
cells. PDGFRα was overexpressed in GBM peritumor tis-
sues derived-CSC compared to counterparts GBM c-CSC,
indicating this pathway a pivotal therapeutic target in
GBM. We also provide the rationale for simultaneous tar-
geting of EGFR and PDGFR, with prospective of an im-
provement of survival and quality of life of GBM patients.
Material and methods
Ethical statement
Procedures for collection of adult human GBM CSC
were approved by the Ethical Committee of the Catholic
University of Rome as reported previously [24]. Informed
consent was obtained and all patients were fully aware of
the aims and scope of this work. The ethical principles of
the declaration of Helsinki were strictly followed.
Cell culture and treatment of human Glioblastoma cancer
stem cells
We have used the same clinical materials reported in
our previous papers [24,25]. In brief, the CSC cells were
retrieved from adult patients affected by GBM and
undergoing craniotomy at the Institute of Neurosurgery,
Catholic University-School of Medicine of Rome, Italy.Dissociated cells were cultured in the presence of human
recombinant EGF (20 ng/ml; PeproTech, Rocky Hill,
NJ), human recombinant bFGF (10 ng/ml; PeproTech),
in DMEM/F12 (1:1) serum-free medium (Invitrogen,
Carlsband, CA) containing L glutamine 2 mM, glucose
0.6%, putrescine 9.6 ug/ml, progesterone 0.025 mg/ml,
sodium selenite 5.2 ng/ml, insulin 0.025 mg/ml, apo-
transferrin sodium salt 0.1 mg/ml, sodium bicarbonate
3 mM, Hepes 5 mM, BSA 4 mg/ml, heparin 4 ug/ml (all
purchased by Sigma-Aldrich). Floating neurospheres were
dissociated with Accutase at 37°C (Merck-Millipore). In
some cases, neurospheres were passaged up to passage
P60 and the experiments were performed between P14
and P60. Cell starvation was planned for 2 days in Stem
Medium w/o EGF and bFGF. Subsequently, PDGF-AA
was added (40 ng/ml, Peprotech) for different time points
(5′, 10′, 30′, 120′ and 24 hours). Cells treatments were
performed with GSI-X (also named L-685,458, Calbiochem),
AG1478 (Calbiochem) and Crenolanib (CP-8685596,
Selleckchem).
ShRNA, transfection and lentivirus production
The experiments on RNA interference were performed
using Mission Lentivirus-based shRNA for PDGFRα (NM_
006206-Sigma-Adrich). We amplified three DNA clones
(clones numbers: TRCN0000195132, TRCN0000196272,
TRCN0000196928) and pLKO.1-puro, as a control for in-
fection. We selected puromycin resistant p-CSC2 express-
ing three different shRNA sequences, but only two were
able to donwmodulate PDGFRα (TRCN0000195132 and
TRCN0000196928). Human embryonic kidney (HEK)-
293 T cells in log-phase growth were transiently trans-
fected using standard LipofectAmine reagent (Invitrogen),
with lentivirus-based shRNA (and with pLKO.1 as con-
trol) plus helper plasmids (Invitrogen Packging Plasmids,
Carlsbard, CA). Media containing the virions were har-
vested two days after cell transfection and transferred
directly onto p-CSC2. Lentiviral infection was per-
formed in the presence of polybrene solution at 8 μg/ml
(Sigma-Aldrich) and the antibiotic puromycin (Euroclone)
was added to the cells at 1 μg/ml for a week to select CSC
expressing shRNA sequences.
Western blots
GBM CSC seeded as single cells (1 × 106/dish) were left
for 1 day in proliferation medium before treating them
for 1-2 days with the inhibitors, either singly or in com-
bination. Afterwards, cells were collected and washed
with PBS plus proteases inhibitors before protein extrac-
tion in 100-200 μl of lysis buffer (1% NP-40, 0.01% SDS,
20 mM Tris–HCl pH 7.4, 300 mM NaCl, 1 mM EDTA,
1 mM Na3VO4 and protease inhibitors cocktail - from
Sigma–Aldrich). Then, cells were sonicated with two
pulses of 5 sec at 50% of amplitude (Sonics and Materials,
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extracts, determined by Bio-Rad protein Assay (Bio-Rad,
Munchen, Germany), were loaded on NuPAGEBis-Tris gels
(Invitrogen), and transferred on Hybond-P Extra mem-
brane (Amersham Biosciences, GE Healthcare Life Science-
Buckinghamshire, UK). Filters were immunoblotted using
the following primary antibodies: rabbit anti-NICD1,
rabbit anti-HES1, rabbit anti-DLL1, rabbit anti-EGFR,
rabbit anti-pY1068-EGFR, rabbit anti-PDGFRα, rabbit
anti-PDGFRβ, rabbit anti-T202/Y204-ERK1/2 and anti-
ERK1/2, rabbit anti-Y705-STAT3 and rabbit anti-STAT3
and anti-Caspase3, (all purchased from Cell Signaling,
MA-USA), mouse anti-S473-AKT1 and rabbit anti-AKT1
(Calbiochem), rabbit anti-BCL2 (Millipore), rabbit anti-
survivin and anti-MMP9 (Abcam), rabbit anti-Cyclin D1
and anti-p27 (Santa Cruz-USA), mouse anti-β-actin and
anti-GAPDH (SIGMA). After three washing with TBS-
Tween buffer, immuno-reactive proteins were detected
using rabbit anti-mouse, donkey-anti-rabbit and donkey
anti-goat horseradish peroxidase-conjugated secondary
antibodies directed to the appropriate primary anti-
bodies (Jackson Immunoresearch Laboratories, West Grove,
PA). The proteins were then visualized using the chemi-
luminescence system (Millipore). Gels and Images ac-
quisition was done by HP Photosmart Essential Ver.
1.12 and Adobe Photoshop CS5 respectively. The
densitometric analysis of protein bands normalized
against to β-actin protein levels were performed from
three independent experiments using the ImageJ software
(NIH, USA).
Cell proliferation assays
For cell proliferation assay, neurospheres were dissoci-
ated into single cells and 1 × 104 cells/well were plated
in triplicate on 60 mm plates. Cells were harvested and
counted at different time points (3, 5, 7 days in vitro) in
growth medium, considering the starting time as the day
after plating. For pharmacological studies we used the
CellTiter 96 Aqueous One Solution Reagent (Promega),
a cell proliferation colorimetric assay containing a novel
tetrazolium compound MTS. Briefly, 2 × 104 cells/well
were plated in triplicate for each group on 12-well
plates and the drugs or DMSO-vehicle were added
the day after plating. Before harvesting cells, they
were incubated with 100 μl/ml of MTS at 37°C for
approximately 1 hour. The metabolically active cells
reduced MTS into a soluble formazan product, whose
absorbance was measured at 490 nm in a plate reader
(Bio-Rad). These experiments were performed three
times and each time in triplicate.The absorbance
values of the collected samples were subtracted from
the background absorbance of medium-only control
and expressed as % of control and calculated as mean
average ± SD (n = 3).RT-PCR and custom RT-PCR array
Total RNA was extracted using Triazol and by RNeasy
mini kit (Qiagen, USA). cDNAs were obtained using
QuantiTect Reverse Transcription kit (Qiagen, USA).
Real time reverse transcriptase PCR (RT-PCR) was car-
ried out in triplicate using SYBR Hi-ROX kit (Bioline,
UK). RT-PCR and a custom RT-PCR array (Microfluidic
Card, Applied Biosystems, CA) were performed with
a 7900HT instrument equipped with SDS2.2 software
(Applied Biosystems, CA). The PCR primers used for
RT-PCR were the following: (Forward) hTBP: GAACAT
CATGGATCAGAACAACA, (Reverse) hTBP: ATAGG
GATTCCGGGAGTCAT; (Forward) hGAPDHAGCCA
CATCGCTCAGACA; (Reverse) hGAPDH: GCCCAA




(Reverse) hEGFR: TTTGGGAACGGACTGGTTTA; (For-
ward) hNOTCH1: CGCACAAGGTGTCTTCCAG; (Re-
verse) hNOTCH1: CGGCGTGTGAGTTGATGA. Relative
levels of expression were obtained by normalization with
respect to selected housekeeper genes (GAPDH, TBP) by
using the ΔCt method following manufacturer’s guide.
Cell invasion assay
For an invasion assay, 1 × 105 cells were resuspended in
0.3 ml of Stem Medium with inhibitors or DMSO-
vehicle and placed in triplicate into the top chamber of
matrigel-coated transwell insert (Millipore). The bottom
wells contained 0.4 ml of Stem Medium with EGF and
bFGF, or without these media as controls for the experi-
ment. After 72 h, cells on the top surface of the filter
were removed with a cottonswab. Thereafter, the filters
were fixed and stained with crystal violet and subse-
quently washed to collect the staining solution. OD
values, proportional to the number of cells, were mea-
sured on a plate reader with a 550 nm filter (Bio-Rad).
These experiments were performed three times and each
time in triplicate. The absorbance values were calculated
as mean ± SD (n = 3). These experiments were repeated
three times and each time in triplicate.
FACS analysis
Cells were fixed with 0.5 ml of cold Methanol/Acetone
Solution (1:5) and left at 4°C for at least 1 hour, then
centrifuged at 950 RPM for 5 minutes. The cell pellet
was resuspended in 100 μl of PBS, 375 ul of Rnase A
(100 μg/ml) and 25 μl of Propidium Iodide (1 mg/ml).
Cells were incubated at room temperature for 15 minutes
and left in the dark at 4°C until FACS analysis. Samples
were acquired on FacsCalibur (BD Becton Dickinson)
at 488 nm. The acquired FACS data were analyzed by
ModFit LT software (Verity Software House, Inc.) to
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G2/M phases. These experiments were performed twice
for each sample.
Statistical analysis
Statistical analysis was performed with Prism5 (GraphPad)
and Microsoft Office Excel 2007. All data shown are repre-
sentative of results obtained from experiments con-
ducted two or three times as specified in the specific
sections. The results were analyzed by either One-way
Anova and Newman-Keuls post-tests or Two-way ANOVA
and Bonferroni’s post tests. Data are expressed as mean ±
standard deviation (SD) and P values ≤0.05 (*), ≤0.01
(**), ≤0.001 (***) were considered statistically significant.
To evaluate the synergistic effect of the combination of
two drugs on cell growth we referred to Lama et al. [50].Additional file
Additional file 1: Figure S1. GSI-X did not modulate survival signals
and cell growth of p-CSC3. (A) Increasing concentrations of GSI-X did not
affect Erk1/2 and Akt1 phosphorylation. (B) Cell growth of p-CSC3 was
not affected by high doses of GSI-X. Values are expressed as mean of ±
SD (n = 4). ns denotes not specific bands.Abbreviations
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